

A1
C054

(b) overexpressing the isolated nucleic acid molecule, wherein said nucleic acid molecule is SEQ ID NO: 2, SEQ ID NO: 22, or SEQ ID NO: 33.--

REMARKS

With entry of this Amendment, claims 49-63 are pending in the application. The claims substantially correspond to claims 23-34, 40, 47, and 48 in grandparent application no. 09/124,238. The claims in that application were subject to a restriction requirement, wherein the examiner asserted that the claims constituted eight separate and distinct inventions. Application are prosecuting the claims of group V in this application.

The computer readable form of the Sequence Listing in this application is identical with that of grandparent application no. 09/124,238, filed July 29, 1998, issued as U.S. Patent No. 6,300,127 on October 9, 2001. In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form submitted on July 29, 1998, in the grandparent application as the computer readable form for this application. It is understood that the U.S. Patent and Trademark Office will make the necessary changes in the application serial number and filing date for the computer readable form that will be used for this application. A paper copy of the sequence listing was included in the application as originally filed.


The undersigned certifies that the content of the paper copy of the Sequence Listing and the computer readable form are the same.

Please grant any extensions of time required to enter this amendment and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: November 9, 2001

By: 
Steven P. O'Connor
Reg. No. 41,225

10001-5298660

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000